169 related articles for article (PubMed ID: 27585671)
1. Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance.
Espinoza SE; Wang CP; Tripathy D; Clement SC; Schwenke DC; Banerji MA; Bray GA; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Stentz FB; Reaven PD; DeFronzo RA; Musi N
Age (Dordr); 2016 Dec; 38(5-6):485-493. PubMed ID: 27585671
[TBL] [Abstract][Full Text] [Related]
2. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the ACT NOW study.
Tripathy D; Cobb JE; Gall W; Adam KP; George T; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Reaven PD; Musi N; Ferrannini E; DeFronzo RA
J Clin Endocrinol Metab; 2015 May; 100(5):1855-62. PubMed ID: 25603459
[TBL] [Abstract][Full Text] [Related]
3. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
[TBL] [Abstract][Full Text] [Related]
4. Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW.
Tripathy D; Clement SC; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Gastaldelli A; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Reaven PD; DeFronzo RA
Diabetes Care; 2014 Jun; 37(6):1706-11. PubMed ID: 24705615
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.
Saremi A; Schwenke DC; Buchanan TA; Hodis HN; Mack WJ; Banerji M; Bray GA; Clement SC; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Tripathy D; DeFronzo RA; Reaven PD
Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):393-9. PubMed ID: 23175674
[TBL] [Abstract][Full Text] [Related]
6. The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone.
DeFronzo RA; Tripathy D; Abdul-Ghani M; Musi N; Gastaldelli A
J Clin Endocrinol Metab; 2014 Oct; 99(10):3774-81. PubMed ID: 24937535
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone for diabetes prevention in impaired glucose tolerance.
DeFronzo RA; Tripathy D; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Hodis HN; Kitabchi AE; Mack WJ; Mudaliar S; Ratner RE; Williams K; Stentz FB; Musi N; Reaven PD;
N Engl J Med; 2011 Mar; 364(12):1104-15. PubMed ID: 21428766
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
9. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates.
Defronzo RA; Tripathy D; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Gastaldelli A; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Reaven PD;
Diabetes; 2013 Nov; 62(11):3920-6. PubMed ID: 23863810
[TBL] [Abstract][Full Text] [Related]
10. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Belfort R; Harrison SA; Brown K; Darland C; Finch J; Hardies J; Balas B; Gastaldelli A; Tio F; Pulcini J; Berria R; Ma JZ; Dwivedi S; Havranek R; Fincke C; DeFronzo R; Bannayan GA; Schenker S; Cusi K
N Engl J Med; 2006 Nov; 355(22):2297-307. PubMed ID: 17135584
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
[TBL] [Abstract][Full Text] [Related]
13. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance.
Durbin RJ
Diabetes Obes Metab; 2004 Jul; 6(4):280-5. PubMed ID: 15171752
[TBL] [Abstract][Full Text] [Related]
15. Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.
Tripathy D; Schwenke DC; Banerji M; Bray GA; Buchanan TA; Clement SC; Henry RR; Kitabchi AE; Mudaliar S; Ratner RE; Stentz FB; Musi N; Reaven PD; DeFronzo RA
J Clin Endocrinol Metab; 2016 May; 101(5):2056-62. PubMed ID: 26982008
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
[TBL] [Abstract][Full Text] [Related]
17. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.
Sourij H; Zweiker R; Wascher TC
Diabetes Care; 2006 May; 29(5):1039-45. PubMed ID: 16644634
[TBL] [Abstract][Full Text] [Related]
18. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.
Bray GA; Smith SR; Banerji MA; Tripathy D; Clement SC; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Musi N; Ratner RE; Schwenke DC; Stentz FB; Reaven PD; DeFronzo RA
Diabetes Obes Metab; 2013 Oct; 15(10):931-7. PubMed ID: 23551856
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
[TBL] [Abstract][Full Text] [Related]
20. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]